Jasper Therapeutics, Inc. (JSPR)
Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE
What they're doing
Between 2026-06-21 and 2026-09-19, public records show 2 signals for Jasper Therapeutics, Inc.. Most notable: 2026-07-17: Filed 8-K disclosing material agreement, acquisition or disposition of assets, director or officer change; 2026-08-26: Filed 8-K disclosing material agreement. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-19 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing material agreement, acquisition or disposition of assets, director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-09-22 | WIGGANS THOMAS G | director | P | 41,000 | 2.43 | $99,630 |
| 2025-09-22 | Lucas Svetlana | director | P | 20,000 | 2.43 | $48,600 |
| 2025-09-22 | MARTELL RON | director | P | 41,000 | 2.43 | $99,630 |
| 2025-09-22 | Shizuru Judith Anne | director | P | 41,000 | 2.43 | $99,630 |
| 2024-12-12 | Mahal Jeetinder Singh | officer | S | 900 | 22.11 | $19,899 |
| 2024-12-12 | Mahal Jeetinder Singh | officer | M | 900 | 7.1 | $6,390 |
| 2024-09-12 | Mahal Jeetinder Singh | officer | M | 900 | 7.1 | $6,390 |
| 2024-09-12 | Mahal Jeetinder Singh | officer | S | 900 | 21.23 | $19,107 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.